Search
ANTI-CANCER IMMUNOTHERAPY TO FIGHT PERSISTENT HIV
CRCHUM researchers are exploring a potential therapeutic approach for treating HIV patients with persistent virus
COMPLETE GENOME SEQUENCE OF STREPTOMYCES OLIVORETICULI ATCC 31159 WHICH CAN PRODUCE ANTICANCER BESTATIN AND SHOW DIVERSE SECONDARY METABOLIC POTENTIALS
Abstract Because of its competitive inhibitor activity against aminopeptidase B, bestatin isolated from the broth of Streptomyces olivoreticuli...
VICE PRESIDENT CLINICAL OPERATIONS & DEVELOPMENT
CureMatch Inc. is a San Diego-based company pioneering a digital precision medicine approach centered on the concept of personalized...
SEMI‐CONTINUOUS SCALE‐DOWN MODELS FOR CLONE AND OPERATING PARAMETER SCREENING IN PERFUSION BIOREACTORS
Perfusion cell culture, confined traditionally to the production of fragile molecules, is currently gaining broader attention in the...
DBV REJOINS PEANUT ALLERGY TREATMENT RACE, BUT AIMMUNE TAKES THE LEAD
DBV Technologies is jumping back into the race to bring an FDA-approved peanut allergy treatment to the market, but it might not be...
GREY WOLF BAGS CASH TO ADVANCE SMALL MOLECULE I/O PROGRAM
Grey Wolf Therapeutics has raised £10 million to advance small molecules that help the immune system recognize tumors. The series A,...
CUREVAC WALKS AWAY FROM ARCTURUS' UREA CYCLE DISORDER DRUG, BUT PARTNERSHIP REMAINS INTACT
Arcturus Therapeutics had a melodramatic 2018 - the San Diego biotech's CEO Joseph Payne was asked to leave for putting his interests...
CANAAN LEAPS INTO UK BIOTECH BY CO-LEADING $14M SERIES A FOR IMMUNO-ONCOLOGY UPSTART GREY WOLF
Checkpoint inhibitors have done wonders for immuno-oncology, but the potent class of drugs doesn't work across all cancers. To remedy...
BIO ROUNDUP: NEW CRISPR FEUD, A NY SPLASH, PHARMA VS. CONGRESS & MORE
If you're into congressional spectacles, stay tuned later this month. A group of top biopharma executives-the full roster isn't known...
HARPOON'S IPO SPEARS $76M AS PROSTATE CANCER DRUG CONTINUES TESTING
Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets, raising approximately $76 million...
FIRST US ATTEMPT TO CURE A RARE DISEASE WITH GENOME EDITING FAILS MISERABLY
Sangamo Therapeutics tried to cure two forms of a rare genetic disease using 'zinc finger' gene editing. They successfully changed...
SERES LAYS OFF 30% OF STAFF, CSO LEAVES AFTER PIPELINE REVIEW
Seres Therapeutics was one of the first microbiome companies to form back in 2010. And the Flagship Pioneering company was the first...
WITH ITS FIRST HUMAN DATA, SOLID SLIPS IN DUCHENNE GENE THERAPY RACE
The race to treat Duchenne muscular dystrophy with gene therapy, a one-time, potentially long-lasting treatment, is being closely watched....
RESEARCH PROVES THE HEALING POTENTIAL OF MONK FRUIT ON CANCER PATIENTS
Monk fruit is one of the stalwarts of traditional Chinese medicine that found new uses in modern times. Many studies are now confirming...
LIGAND ANNOUNCES INVESTMENT IN DIANOMI THERAPEUTICS
SAN DIEGO--Ligand Pharmaceuticals Incorporated announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company...
ARGENX AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR ENHANZE® TECHNOLOGY
Argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic...
DEWPOINT DEBUTS WITH $60M TO TARGET PROTEIN DROPLETS LINKED TO DISEASE
An exciting new area of cell biology research that has emerged in only the last decade has already spawned a startup, which launches...
SCALING UP THE MANUFACTURING PROCESS OF ADOPTIVE T CELL IMMUNOTHERAPY
Standardizing the manufacturing process is of the ultimate importance for scaling up Adoptive Cell Therapy , where closed system, automation,...
LECITHIN NANO-LIPOSOMAL PARTICLE AS A CRISPR/CAS9 COMPLEX DELIVERY SYSTEM FOR TREATING TYPE 2 DIABETES
Protein-based Cas9 in vivo gene editing therapeutics have practical limitations owing to their instability and low efficacy. To overcome...
GILEAD, GATES FOUNDATION JOIN LYNDRA'S $55M FUNDING FOR PHASE 2 TESTS
Lyndra Therapeutics, a startup whose technology turns daily pills into extended-release formulations intended to last a week or longer,...